Comparative Pharmacology
Head-to-head clinical analysis: ETOMIDATE versus KETALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETOMIDATE versus KETALAR.
ETOMIDATE vs KETALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.
Noncompetitive NMDA receptor antagonist; inhibits glutamate activity, modulates opioid receptors, and interacts with other neurotransmitter systems.
Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.
1-4.5 mg/kg IV or 6.5-13 mg/kg IM for induction of anesthesia; 0.1-0.5 mg/kg/min IV infusion for maintenance.
None Documented
None Documented
Clinical Note
moderateEtomidate + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Etomidate is combined with Fluticasone propionate."
Clinical Note
moderateEtomidate + Clemastine
"The risk or severity of adverse effects can be increased when Etomidate is combined with Clemastine."
Clinical Note
moderateEtomidate + Venlafaxine
"Etomidate may decrease the antihypertensive activities of Venlafaxine."
Clinical Note
moderateEtomidate + Nefazodone
Terminal elimination half-life: 2.9–5.3 hours (context: redistribution shortens clinical effect; hepatic impairment prolongs).
Terminal elimination half-life: 2.5-3 hours (ketamine); norketamine: 12 hours. Clinical context: Short half-life facilitates rapid recovery, but context-sensitive half-life increases with infusion duration.
Renal: 75% as metabolite (carboxylic acid), 2% unchanged; fecal/biliary: minimal.
Renal: 90% as metabolites (norketamine, dehydronorketamine); unchanged: 2-4%. Fecal: <3%.
Category C
Category C
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Etomidate is combined with Nefazodone."